The Gastrointestinal Stromal Tumor (GIST) Therapeutics Market is estimated to be valued at USD 1000.0 million in 2025 and is projected to reach USD 1790.9 million by 2035, registering a compound annual growth rate (CAGR) of 6.0% over the forecast period.
-therapeutics-market-market-value-analysis.webp "Gastrointestinal Stromal Tumor (gist) Therapeutics Market Market Value Analysis")
| Metric | Value |
|---|---|
| Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Estimated Value in (2025 E) | USD 1000.0 million |
| Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Forecast Value in (2035 F) | USD 1790.9 million |
| Forecast CAGR (2025 to 2035) | 6.0% |
The gastrointestinal stromal tumor therapeutics market is expanding steadily due to the rising prevalence of GIST cases, improvements in diagnostic accuracy, and the growing availability of advanced targeted therapies. Increased awareness among healthcare providers, coupled with patient preference for effective treatment regimens with manageable side effects, is influencing adoption trends.
Significant progress in molecular research has facilitated the development of targeted agents that specifically address mutations associated with GIST, improving patient survival rates. Regulatory approvals of novel therapies and expanded indications for existing drugs are further strengthening market dynamics.
Hospitals and specialized cancer centers are increasingly focusing on treatment standardization and access to innovative therapies, ensuring wider adoption. The market outlook remains positive as investment in precision medicine, improved patient access to oncology care, and advancements in drug development continue to drive therapeutic growth in this segment.
-therapeutics-market-analysis-by-drug-type.webp "Gastrointestinal Stromal Tumor (gist) Therapeutics Market Analysis By Drug Type")
The imatinib drug type segment accounts for 41.70% of the market revenue by 2025, positioning it as the leading drug type. Its dominance is attributed to its role as the first line therapy in GIST treatment, backed by strong clinical efficacy and long term patient outcomes.
Imatinib has demonstrated high effectiveness in controlling tumor progression, delaying recurrence, and improving overall survival rates. Continuous physician preference for imatinib as the standard of care, combined with its broad accessibility across developed and emerging markets, has reinforced its widespread adoption.
The availability of generic formulations has further expanded patient access, solidifying imatinib’s position as the cornerstone of GIST therapy.
-therapeutics-market-analysis-by-therapy.webp "Gastrointestinal Stromal Tumor (gist) Therapeutics Market Analysis By Therapy")
The targeted therapy segment holds 56.30% of market revenue by 2025, making it the leading therapeutic approach. Growth is being driven by the rising emphasis on precision oncology and the ability of targeted drugs to address specific genetic mutations in GIST patients.
Targeted therapies offer improved efficacy, reduced systemic toxicity, and enhanced quality of life compared to conventional chemotherapy. Regulatory bodies and research institutions have continued to prioritize investment in targeted agents, resulting in expanded treatment options.
Their growing adoption reflects a shift in oncology treatment models toward individualized care, establishing targeted therapy as the preferred therapeutic pathway in GIST management.
-therapeutics-market-analysis-by-end-user.webp "Gastrointestinal Stromal Tumor (gist) Therapeutics Market Analysis By End User")
The hospitals segment is projected to capture 62.40% of market revenue by 2025, emerging as the dominant end user. This is due to the concentration of advanced diagnostic facilities, availability of oncology specialists, and integration of multidisciplinary treatment approaches within hospitals.
Patients undergoing GIST treatment typically require continuous monitoring, advanced imaging, and specialized care, which hospitals are well equipped to provide. Hospitals also serve as primary centers for clinical trials and adoption of newly approved therapies, ensuring faster patient access to innovative treatment options.
The combination of infrastructure, expertise, and access to comprehensive care has reinforced hospitals as the leading end user segment in the GIST therapeutics market.
According to market research and competitive intelligence provider Future Market Insights- the market for Gastrointestinal stromal tumor (GIST) therapeutics reflected a value of 3.5% during the historical period, 2020 to 2025.
The Gastrointestinal Stromal Tumor (GIST) Therapeutics Market was growing during the period from 2020 to 2025. The growth was primarily driven by the increasing incidence of gastrointestinal stromal tumors and the approval of new drugs for the treatment of GIST. In addition, the rising awareness about GIST and the availability of advanced therapies are also contributing to the growth of the market. However, the high cost of treatment and the limited number of approved drugs may hinder the growth of the market.
Thus, the market for Gastrointestinal stromal tumor (GIST) therapeutics is expected to register a CAGR of 6% in the forecast period 2025 to 2035.
Demand for effective therapies driving growth for GIST therapeutics market
The incidence of GIST is increasing worldwide, which is driving the demand for effective treatment options. As GIST is a difficult cancer to treat, there remains a significant unmet medical need for new and effective therapies. Moreover, development of new technologies, such as tyrosine kinase inhibitors (TKIs), has led to improved treatment outcomes for patients with GIST.
Furthermore, increasing awareness about GIST and its treatment options, among healthcare providers and patients, is driving demand for GIST therapeutics. In addition, governments around the world are providing support for cancer research and drug development, which is helping to drive growth in the GIST therapeutics market.
Availability of various treatments creating lucrative opportunities for GIST therapeutics market
As GIST cannot be completely treated with surgery, the dependency on various therapeutics has increased. Moreover, healthcare professionals are suggesting different therapeutics methods that would cater to the condition of the patients.
Surgery: Surgical removal of the tumor is the primary treatment option for localized GISTs.
Imatinib: This is a tyrosine kinase inhibitor (TKI) that targets the KIT and PDGFRA genes that are often mutated in GISTs. Imatinib is the first-line therapy for advanced GISTs.
Sunitinib: This is another TKI that is used as a second-line treatment for patients who have developed resistance to imatinib.
Regorafenib: This is another TKI that is used as a third-line treatment for patients who have become resistant to both imatinib and sunitinib.
Radiation therapy: Radiation therapy may be used in conjunction with surgery or as palliative treatment for GISTs that cannot be surgically removed.
Chemotherapy: Chemotherapy is generally not effective in treating GISTs, but it may be used in combination with other therapies.
-therapeutics-market-cagr-analysis-by-country.webp "Gastrointestinal Stromal Tumor (gist) Therapeutics Market Cagr Analysis By Country")
Lengthy approval process and drug resistance restricting market growth
The cost of GIST treatments, especially targeted therapies and other innovative drugs is high. This, in turn, limits access to these treatments for some patients. GIST is a relatively rare type of cancer, which means that the market for GIST therapeutics is smaller compared to other cancer indications.
As patents for GIST treatments expire, generic versions of these drugs may become available, which can decrease the market share and profitability of brand-name treatments. Some patients with GIST may develop resistance to TKIs, which can limit the effectiveness of these treatments over time.
The approval process for new drugs can be lengthy and expensive, and there is always the risk that a new treatment may not be approved by regulatory agencies. Some GIST treatments can cause adverse effects, such as nausea, vomiting, fatigue, and low blood counts, which can impact patient quality of life and limit the use of these treatments. All these factors are hampering the growth of the GIST market.
Introduction of new and innovative therapies creating lucrative opportunities for GIST therapeutics
The North American market for Gastrointestinal Stromal Tumor (GIST) therapeutics is one of the largest and most mature markets globally, driven by factors such as a large and aging patient population, high levels of healthcare spending, and a strong presence of pharmaceutical companies. The United States is the largest market for GIST therapeutics in North America, accounting for the majority of sales in the region.
In recent years, the North American market for GIST therapeutics has seen steady growth due to the increasing incidence of GIST, the introduction of new and innovative therapies, and growing demand for effective treatments. The availability of targeted therapies, such as tyrosine kinase inhibitors (TKIs), has been a major driver of growth in the market, as these drugs have proven to be highly effective in treating GIST. Thus, North America is expected to possess 39% market share for GIST therapeutics market in 2025.
Growing prevalence of GIST in aging population propelling market growth
The Asia Pacific market for gastrointestinal stromal tumor (GIST) therapeutics is a rapidly growing market, driven by factors such as increasing incidence of GIST, rising levels of healthcare spending, and a growing middle-class population. The market is expected to continue to grow in the coming years, driven by factors such as the increasing availability of targeted therapies, such as tyrosine kinase inhibitors (TKIs), and the growing awareness of GIST among healthcare providers and patients.
Despite these challenges, the Asia Pacific market for GIST therapeutics is expected to continue to grow in the coming years, driven by increasing demand for effective treatments, advances in research and development, and improving economic conditions in the region. The market is also likely to benefit from the growing aging population and the increasing incidence of GIST, which are expected to drive demand for GIST treatments in the future. Thus, Asia Pacific is expected to hold 31% market share for GIST therapeutics market in 2025.
Presence of innovative drugs and technology making hospitals a viable option for treatment of GIST therapeutics
Hospitals have a high level of expertise in treating complex and rare diseases such as GIST, and often have a dedicated team of specialists who are experienced in diagnosing and treating the condition. In addition, hospitals provide comprehensive care for GIST patients, including surgery, chemotherapy, radiation therapy, and targeted therapies such as tyrosine kinase inhibitors (TKIs). Access to the latest technologies and treatments, including innovative drugs and cutting-edge diagnostic and therapeutic tools, which can improve patient outcomes are making hospitals a go-to option for patients suffering frm GIST.
Moreover, strict quality and safety standards ensure that patients receive high-quality care and are protected from medical errors. In addition, hospitals offer the convenience of having all necessary diagnostic and therapeutic services in one location, reducing the need for multiple trips to different healthcare providers. Thus, hospitals are expected to procure 45% market share for GIST therapeutics market in 2025.
-therapeutics-market-analysis-by-company.webp "Gastrointestinal Stromal Tumor (gist) Therapeutics Market Analysis By Company")
Key players in the gastrointestinal stromal tumor (GIST) therapeutics market are Arog Pharmaceuticals, Taiho Pharmaceutical, Turning Point Therapeutics, Inc, Cogent Biosciences, Inc, Plexxikon Inc, Theseus Pharmaceuticals, Exelixis, Inc, Ipse, Bristol-Myers Squibb and Takeda
| Report Attribute | Details |
|---|---|
| Market Value in 2025 | USD 1000.0 million |
| Market Value in 2035 | USD 1790.9 million |
| Growth Rate | CAGR of 6% from 2025 to 2035 |
| Base Year for Estimation | 2025 |
| Historical Data | 2020 to 2025 |
| Forecast Period | 2025 to 2035 |
| Quantitative Units | Revenue in USD Million and CAGR from 2025 to 2035 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Drug Type, Therapy, End User, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; MEA |
| Key Countries Profiled | USA, Canada, Brazil, Argentina, Germany, United kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC, South Africa |
| Key Companies Profiled | Arog Pharmaceuticals; Taiho Pharmaceutical; Turning Point Therapeutics, Inc.; Cogent Biosciences, Inc.; Plexxikon Inc.; Theseus Pharmaceuticals; Exelixis, Inc.; Ipsen; Bristol-Myers Squibb; Takeda |
| Customization | Available Upon Request |
The global gastrointestinal stromal tumor (gist) therapeutics market is estimated to be valued at USD 1,000.0 million in 2025.
The market size for the gastrointestinal stromal tumor (gist) therapeutics market is projected to reach USD 1,790.9 million by 2035.
The gastrointestinal stromal tumor (gist) therapeutics market is expected to grow at a 6.0% CAGR between 2025 and 2035.
The key product types in gastrointestinal stromal tumor (gist) therapeutics market are imatinib, ripretinib, crenolanib, regorafenib, avapritinib, sunitinib, entrectinib and larotrectinib.
In terms of therapy, targeted therapy segment to command 56.3% share in the gastrointestinal stromal tumor (gist) therapeutics market in 2025.
Explore Similar Insights
Gastrointestinal Stromal Tumor (GIST) Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
